Skye Depreciation And Amortization vs Income Before Tax Analysis

SKYE Stock  USD 2.46  0.20  7.52%   
Skye Bioscience, financial indicator trend analysis is much more than just breaking down Skye Bioscience, Common prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Skye Bioscience, Common is a good investment. Please check the relationship between Skye Bioscience, Depreciation And Amortization and its Income Before Tax accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Depreciation And Amortization vs Income Before Tax

Depreciation And Amortization vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Skye Bioscience, Common Depreciation And Amortization account and Income Before Tax. At this time, the significance of the direction appears to have pay attention.
The correlation between Skye Bioscience,'s Depreciation And Amortization and Income Before Tax is -0.84. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Skye Bioscience, Common, assuming nothing else is changed. The correlation between historical values of Skye Bioscience,'s Depreciation And Amortization and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Skye Bioscience, Common are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Depreciation And Amortization i.e., Skye Bioscience,'s Depreciation And Amortization and Income Before Tax go up and down completely randomly.

Correlation Coefficient

-0.84
Relationship DirectionNegative 
Relationship StrengthSignificant

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Skye Bioscience, income statement and is an important metric when analyzing Skye Bioscience, Common profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.
Most indicators from Skye Bioscience,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Skye Bioscience, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
At present, Skye Bioscience,'s Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting.
 2021 2022 2023 2024 (projected)
Tax Provision2.1K6.7K3.6K3.0K
Income Tax Expense2.1K6.7K3.6K2.8K

Skye Bioscience, fundamental ratios Correlations

0.9-0.21-0.530.3-0.560.340.550.430.250.370.44-0.83-0.50.070.350.390.480.97-0.420.36-0.860.190.130.360.39
0.90.17-0.810.52-0.710.660.820.740.280.690.66-0.6-0.650.130.680.350.250.95-0.10.71-0.670.190.140.620.63
-0.210.17-0.670.74-0.450.570.630.760.390.790.730.65-0.530.340.770.11-0.370.010.90.730.580.020.330.750.6
-0.53-0.81-0.67-0.690.81-0.87-0.99-0.95-0.3-0.9-0.860.080.82-0.28-0.91-0.180.07-0.69-0.46-0.930.15-0.11-0.14-0.85-0.85
0.30.520.74-0.69-0.530.40.640.780.740.830.860.17-0.560.30.730.570.160.490.490.650.090.340.70.810.57
-0.56-0.71-0.450.81-0.53-0.52-0.84-0.77-0.5-0.67-0.730.160.89-0.42-0.67-0.35-0.21-0.66-0.35-0.610.20.09-0.33-0.64-0.54
0.340.660.57-0.870.4-0.520.830.78-0.180.750.61-0.05-0.490.010.82-0.2-0.40.480.370.94-0.110.14-0.320.680.88
0.550.820.63-0.990.64-0.840.830.940.320.870.85-0.1-0.880.360.890.19-0.050.70.460.89-0.170.010.140.820.8
0.430.740.76-0.950.78-0.770.780.940.430.980.930.09-0.790.480.980.19-0.150.610.590.930.010.160.290.940.8
0.250.280.39-0.30.74-0.5-0.180.320.430.440.550.08-0.560.480.310.790.550.330.290.120.050.040.980.41-0.02
0.370.690.79-0.90.83-0.670.750.870.980.440.930.14-0.680.440.990.21-0.20.560.590.930.060.240.330.950.78
0.440.660.73-0.860.86-0.730.610.850.930.550.930.13-0.770.560.910.27-0.080.620.590.810.060.260.430.980.8
-0.83-0.60.650.080.170.16-0.05-0.10.090.080.140.130.050.340.15-0.27-0.57-0.70.830.070.99-0.090.140.20.02
-0.5-0.65-0.530.82-0.560.89-0.49-0.88-0.79-0.56-0.68-0.770.05-0.57-0.68-0.33-0.19-0.6-0.48-0.590.090.19-0.37-0.67-0.52
0.070.130.34-0.280.3-0.420.010.360.480.480.440.560.34-0.570.47-0.06-0.140.140.570.230.330.020.390.550.16
0.350.680.77-0.910.73-0.670.820.890.980.310.990.910.15-0.680.470.06-0.310.530.610.960.070.220.190.950.83
0.390.350.11-0.180.57-0.35-0.20.190.190.790.210.27-0.27-0.33-0.060.060.650.41-0.14-0.01-0.31-0.190.790.12-0.11
0.480.25-0.370.070.16-0.21-0.4-0.05-0.150.55-0.2-0.08-0.57-0.19-0.14-0.310.650.4-0.49-0.35-0.540.120.55-0.26-0.36
0.970.950.01-0.690.49-0.660.480.70.610.330.560.62-0.7-0.60.140.530.410.4-0.230.54-0.750.260.20.550.56
-0.42-0.10.9-0.460.49-0.350.370.460.590.290.590.590.83-0.480.570.61-0.14-0.49-0.230.520.8-0.070.230.620.43
0.360.710.73-0.930.65-0.610.940.890.930.120.930.810.07-0.590.230.96-0.01-0.350.540.52-0.020.21-0.010.870.89
-0.86-0.670.580.150.090.2-0.11-0.170.010.050.060.060.990.090.330.07-0.31-0.54-0.750.8-0.02-0.10.110.12-0.05
0.190.190.02-0.110.340.090.140.010.160.040.240.26-0.090.190.020.22-0.190.120.26-0.070.21-0.10.090.310.3
0.130.140.33-0.140.7-0.33-0.320.140.290.980.330.430.14-0.370.390.190.790.550.20.23-0.010.110.090.3-0.14
0.360.620.75-0.850.81-0.640.680.820.940.410.950.980.2-0.670.550.950.12-0.260.550.620.870.120.310.30.85
0.390.630.6-0.850.57-0.540.880.80.8-0.020.780.80.02-0.520.160.83-0.11-0.360.560.430.89-0.050.3-0.140.85
Click cells to compare fundamentals

Skye Bioscience, Account Relationship Matchups

Skye Bioscience, fundamental ratios Accounts

201920202021202220232024 (projected)
Other Current Liab410.6K341.8K954.9K7.6M8.3M4.7M
Total Current Liabilities970.8K787.2K3.9M12.1M13.9M14.6M
Net Tangible Assets(15.6M)548.1K450.8K5.9M6.7M7.1M
Retained Earnings(32.2M)(38.7M)(47.3M)(66.7M)(104.4M)(99.2M)
Accounts Payable129.8K381.4K900.0K1.8M1.2M653.5K
Other Current Assets12.1K195.0K629.1K412.0K11.0M11.5M
Total Current Assets2.0M2.7M9.6M8.9M11.7M12.2M
Common Stock182.9K288.1K476.1K913.5K12.3K11.7K
Property Plant Equipment3.4K2.0K7.3K234.7K269.9K283.4K
Total Assets2.0M2.7M9.9M9.1M11.9M6.0M
Total Stockholder Equity548.1K450.8K5.9M(3.0M)(2.1M)(2.2M)
Cash1.8M2.5M9.0M1.2M1.3M1.2M
Non Current Assets Total2.0K7.3K243.0K167.4K289.6K304.0K
Common Stock Shares Outstanding182.9M1.0M1.7M493.7M7.0M6.7M
Non Current Liabilities Total477.9K1.4M78.7K1.7M171.2K162.7K
Total Liab1.4M2.2M4.0M12.1M14.1M8.3M
Net Invested Capital935.1K1.9M7.8M(1.2M)2.2M2.4M
Net Working Capital1.0M1.9M5.7M(3.2M)(2.3M)(2.4M)
Capital Stock182.9K288.1K476.1K913.5K12.3K11.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.60)
Return On Assets
(0.30)
Return On Equity
(0.55)
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.